Background: Ureaplasma spp. in the maternal genitourinary tract has come to attention as a cause of preterm labor, spontaneous abortion, chorioamnionitis and adverse outcomes. A few controversies, however, still remain, namely, whether it should be treated aggressively or not. The aim of this study was to evaluate the effect of maternal azithromycin (AZ) treatment for Ureaplasma colonization on neonatal morbidities including bronchopulmonary dysplasia (BPD).
Despite recent tremendous developments in the field of neonatology, bronchopulmonary dysplasia (BPD) remains a major cause of morbidity in premature infants. 1, 2 The etiology of BPD seems to be multifactorial and includes hyperoxia, barotrauma, surfactant deficiency, nutritional deficiency, fluid overload, patent ductus arteriosus (PDA), and lung inflammation and infection.
3, 4 Of these factors, prolonged exposure to inflammation initiated in utero by intrauterine infection plays a critical role in altering lung development. A long duration of inflammatory response and increases in fibrotic reactions in animals play critical roles in the development of BPD. 4, 5 Ureaplasma spp. are frequently isolated microorganisms in amniotic fluid and infected placentas. 6, 7 Although Ureaplasma spp. are isolated from the vagina in 40-80% of sexually active asymptomatic women as commensal organisms, these bacteria can cause preterm delivery, spontaneous abortion or miscarriage, chorioamnionitis, neonatal morbidity, and/or perinatal death. 8, 9 Ureaplasma spp. can be transmitted vertically from the mother to the fetus in utero or to the newborn infant at delivery. 10, 11 In one study, the risk of moderate-severe BPD development was increased 7.9-fold in mechanically ventilated preterm infants being ventilated for any reason who had Ureaplasma-positive tracheal aspirates. 12 Some studies have evaluated the use of erythromycin for treating maternal Ureaplasma colonization because this medication was once the standard antibiotic for the treatment of preterm premature rupture of membranes (PPROM). [13] [14] [15] Currently, however, azithromycin (AZ), an expanded-spectrum macrolide, is thought to have better tissue penetration than erythromycin; hence, it seems to be a good alternative antibiotic. 16, 17 Recent studies in rhesus monkeys have suggested that antenatal multiple-dose AZ could mitigate pregnancy-associated complications, and another study in a sheep model also showed promising results. 18, 19 Few studies, however, have evaluated the effectiveness of antenatal AZ treatment for improving neonatal outcomes in preterm infants, therefore the question of whether maternal AZ treatment is effective is still being debated.
Thus, the aim of this study was to demonstrate the clinical effects of antenatal AZ treatment of Ureaplasma-colonized mothers on neonatal morbidity including BPD.
Methods

Subjects
All preterm infants born at ≤30 weeks of gestational age (GA) who were admitted to Hallym University Medical Center from January 2012 to December 2016 were enrolled in this study. The following infants were excluded: those born with incomplete or prophylactic antenatal AZ treatment; those without maternal Ureaplasma colonization results; those who were transferred to or from other institutes for any reason; those without complete medical charts; or those who died before 28 days of life, making it impossible to diagnose BPD. Infants born to Ureaplasma-colonized mothers with complete maternal AZ treatment (m-AZ, cases) were compared with those born to women without Ureaplasma colonization (controls). Due to the nature of Ureaplasma colonization, which is by vertical transmission, the m-AZ subjects were divided by neonatal respiratory Ureaplasma status into two groups: infants with respiratory Ureaplasma colonization (nUU(+)), and infants without colonization (nUU(-)). The m-AZ subjects were matched to the control subjects by GA. This retrospective single-center case-control study was approved by the institutional review of the boards of our facility members, and they allowed a waiver of informed consent.
Ureaplasma confirmation and azithromycin treatment
Ureaplasma samples from the lower genital tract were obtained from mothers who were admitted for any reason, using vaginal swabs during physical examination. MYCOFAST â Evolution 2 (International Microbio, Signes, France) was used for culture analysis, and if the interval between admission and delivery was >1 week, the microbiological examinations were repeated. To obtain a sufficient amount of sample, all procedures were performed twice. When at least one out of two results was confirmed positive, it was defined as Ureaplasma colonization, and antenatal AZ treatment was carried out. Complete antenatal treatment was defined as oral AZ 500 mg/day for 3 consecutive days before delivery.
For neonates, to determine the rate of vertical transmission in the respiratory tract, neonatal samples were collected from each infant using either tracheal aspiration (intubated infants) or nasopharyngeal swabs (non-intubated infants). These samples were obtained on day 1 and 3 after birth when the mothers were confirmed to have Ureaplasma colonization. Realtime polymerase chain reaction (PCR) was used to detect Ureaplasma colonization. DNA extraction was performed with the QIAamp viral RNA kit (Qiagen, Hilden, Germany), and primers of 14b (5 0 -CCAGGAAAACTACCAGGA-3 0 ) and c72b (5 0 -CTCCTAATCTAACGA-3 0 ) were used.
Definition of parameters
The maternal and clinical variables such as GA, birthweight, preterm labor, PPROM, antenatal steroids, chorioamnionitis, respiratory distress syndrome (RDS), BPD, PDA, sepsis, and cranial sonographic abnormalities were compared. Preterm premature rupture of membranes was defined as rupture of membranes verified ≥24 h before delivery. Mothers who had a fever >37.8°C and two or more of the following were diagnosed with chorioamnionitis: leukocytosis (≥15 000/ lL), elevated C-reactive protein, foul odor, maternal tachycardia (>100 beats/min), and/or fetal tachycardia (>160 beats/ min).
Sepsis was diagnosed on the basis of positive blood culture, along with any demonstrated compatible clinical signs. PDA treatment was defined as echocardiography, diagnosis of PDA and medical treatment and/or surgery. BPD was diagnosed as oxygen dependency at 36 weeks of postmenstrual age according to the consensus definition of the National Institutes of Health, and the severity was classified as mild, moderate, or severe. 20 Abnormalities in cranial sonography were defined as intraventricular hemorrhage (≥grade 2) AE periventricular leukomalacia.
Statistical analysis
Statistical analysis was performed using Student's t-test and ANOVA for normally distributed data, and the chi-squared test or Fisher's exact test for comparisons between frequencies. Post-hoc analysis was also performed. All statistical analysis was performed with SPSS (version 22, IBM, Armonk, NY, USA). Data are reported as mean AE SD or number (%). Statistical significance was accepted at P < 0.05.
Results
During the study period, 230 preterm infants were admitted to the present neonatal intensive care unit. Of these, 161 infants ≤30 weeks of GA were born to women with maternal Ureaplasma colonization. Thirty-three infants were excluded because their mothers were untreated or had received incomplete treatment from the beginning. Of the remaining 128 m-AZ infants, 16 died or were transferred during neonatal hospitalization, and two were excluded due to incomplete medical records. Thus, the subjects consisted of 110 m-AZ infants (i.e. 55 Ureaplasma colonized infants, nUU(+); and 55 non-colonized infants, nUU(-)), and 55 matched control infants.
When comparing the m-AZ and control subjects, the incidence of PPROM was significantly higher in the m-AZ group (59/110, 54%) than in the control group (16/55, 29.1%; P = 0.003). Other maternal variables including preterm labor, antenatal steroid, and chorioamnionitis were not significantly different between the m-AZ and control subjects. In terms of neonatal morbidity, mean GA and birthweight were not different between the two groups (P = 0.798 and P = 0.788, respectively). The incidences of RDS, PDA with treatment, sepsis, and abnormal brain sonography were not different between the m-AZ and control subjects. Furthermore, although the incidence of BPD seemed to be higher in the m-AZ group (26%, 26/110) than in the control group (16%, 9/55), there was no significant difference between the two groups (P = 0.173). The incidence of moderate-severe BPD, however, was significantly different in the m-AZ group, 24% (26/110) vs 7% (4/55) in the control group (P = 0.010; Table 1 ).
When we divided the neonates into three groups by Ureaplasma status, mean GA and birthweight were not significantly different between the m-AZ + nUU(+), m-AZ + nUU(-), and control groups. There was a significant difference, however, in the incidence of PPROM (P = 0.010). On post-hoc analysis the difference in PPROM between the m-AZ + nUU(+) and control groups was also ignificant (P = 0.04). In terms of the incidence of BPD, there was no significant difference between the three groups: m-AZ + nUU(+) group, 26% (14/55); m-AZ + nUU(-) group, 27% (15/55); and control group, 16% (9/55). Fourteen of 55 infants in the m-AZ + nUU(+) group (26%) had moderatesevere BPD, while 12 infants in the m-AZ + nUU(-) group (22%) had moderate-severe BPD. When the incidence of moderate-severe BPD was compared between the three groups, there was a significant difference (P = 0.033), and on post-hoc analysis the difference between the m-AZ + nUU(+) and control groups was also significant (P = 0.040; Table 2 ). .2) 0.557 † Post-hoc analysis: *P < 0.05, m-AZ + nUU(+) vs control. BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; m-AZ, maternal Ureaplasma colonization and azithromycin treatment; nUU(+), infants with respiratory Ureaplasma colonization; nUU(-), infants without colonization; PDA, patent ductus arteriosus; PPROM, preterm premature rupture of membrane; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome.
Discussion
In this retrospective case-control study, we have demonstrated that maternal Ureaplasma colonization was significantly associated with PPROM and moderate-severe BPD despite antenatal AZ treatment.
Many studies have shown that the isolation of Ureaplasma from the placenta or the lower genital tract during pregnancy plays a causal role in the process of intrauterine inflammation and infection-driven preterm labor. 1, 19, 21, 22 Hence, as Acosta et al. noted, preterm delivery caused by intrauterine infection is potentially "preventable", and maternal antibiotics can be used to prevent and treat intrauterine infection. 18 Their study involving non-human primates showed that repeated i.v. doses of maternal AZ accumulated sufficiently to clear U. parvum from the amniotic fluid. 18 Another study involving an ovine model conducted by Miura et al. also showed that maternal antenatal treatment with either i.v. AZ alone or i.v. + intraamniotic AZ effectively eradicated macrolide-sensitive U. partum from the amniotic fluid. 19 In the present study, the incidences of preterm labor and chorioamnionitis in preterm infants ≤30 weeks of GA matched by GA were not different between the antenatal AZ treated group and the non-colonized group. These findings might explain the effectiveness of antenatal treatment with AZ.
Vertical transmission leading to neonatal respiratory colonization from Ureaplasma-colonized mothers to infants has been reported to affect 58% of preterm infants and 22-55% of full-term infants. 23, 24 Ureaplasma isolation in the preterm respiratory tract is associated with neonatal pneumonia, severe respiratory failure, and BPD. 18 Since three independent groups first reported the association between lower respiratory tract Ureaplasma colonization in very preterm infants and the development of chronic lung disease in 1988, numerous studies regarding Ureaplasma colonization and BPD with different results have been reported. 9, 25, 26 One study by Sung et al. demonstrated that the risk of developing moderate-severe BPD increased by 7.9-fold in mechanically ventilated infants with positive tracheal aspirates compared with mechanically ventilated infants with positive nasopharyngeal samples alone. 12 The associations between respiratory tract Ureaplasma colonization and BPD have been confirmed in many studies, even though GA appears to be a major confounder. [27] [28] [29] Recently, studies regarding the effects of macrolide antibiotics including erythromycin and/or AZ given either prophylactically or therapeutically to reduce BPD or other neonatal morbidities with different results have been reported. 5, 13, 30 A systematic review and meta-analysis showed promising results of prophylactic AZ therapy in terms of a significant reduction in BPD, 5 while a very recent case-control study demonstrated no significant therapeutic effect of erythromycin on pulmonary short-and long-term morbidity. 2 Nevertheless, studies regarding the effects of antenatal macrolide treatment on neonatal morbidities are sparse. In the present study, the incidence of BPD was similar between the antenatal AZ-treated group and the noncolonized group, showing that maternal AZ treatment was an effective method of reducing the incidence of BPD. Even when the vertical transmission was suspected due to the presence of neonatal respiratory Ureaplasma colonization, the incidence of BPD was similar. Antenatal treatment, however, was not effective for reducing the development of moderate-severe BPD in preterm infants ≤30 weeks of GA. Hence, the use of a single antibiotic to eradicate intrauterine infection may not be as sufficient as other studies have reported, and additional anti-inflammatory therapy or selective postnatal treatment might be needed to reduce the development of moderate or severe BPD. 19, 31, 32 There were a number of limitations in our study. First, varying antenatal antibiotics other than AZ were used, and we could not control all the antibiotics used given that this was a retrospective study. Given that this was a single-center study, however, similar antibiotics were mostly used apart from AZ. Second, follow-up Ureaplasma culture and/or PCR was not implemented to confirm Ureaplasma-negative conversion. Due to these limitations, a large-scale randomized controlled study needs to be conducted as soon as possible to confirm or thoroughly examine the present results.
In conclusion, maternal Ureaplasma colonization was associated with the development of moderate-severe BPD in preterm infants despite the use of complete antenatal AZ treatment. Hence, selective antenatal treatment together with postnatal antibiotic treatment to reduce Ureaplasma colonization is needed to improve neonatal outcome.
